Stock Alert for S1 Corp. (SONE)
  • Stock Alert for Bank of America Corp. (BAC)
  • Stock Alert for ON Semiconductor Corp. (ONNN)
  • " />

    Stock Alert for Boston Scientific Corp. (BSX)

    Boston Scientific Corp. (BSX) is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. During the year ended December 31, 2010, the Company’s products were offered for sale by seven business groups: CRM, Cardiovascular, including International Cardiology and Peripheral Interventions businesses; Electrophysiology; Endoscopy; Urology/Women’s Health; Neuromodulation, and Neurovascular. During 2010, it had 28% of net sales from CRM business, 42% from Cardiovascular group, 2% from Electrophysiology business, 14% form Endoscopy business, 6% from Urology/Women’s Health business, 4% from Neuromodulation business, and 4% from Neurovascular business.

    Share Statistics (28-July-11)   FY












    Symbol BSX Revenue, $Mn 8,188.0 7,806.0 -4.7% 1,960.0 1,925.0 -1.8%
    Current price $7.26 Gross marg. 68.5% 66.7% -2.6% 66.2% 67.2% 1.5%
    52wk Range: $5.04-$7.96 Oper. margin -8.4% 16.7%
    Avg Vol (3m): 20,384,900 Net margin -12.5% -13.6% 8.8% -81.1% 2.4% -103.0%
    Market Cap. 11.09B              
    Shares Outstanding 1.53B EPS, $ 0.27 0.03 -88.9% -0.31 0.02 -106.5%

    Source:, SEC Filings.

    Recent News

    BSX soared 8.20% to close Thursday at $7.26 following the medical device maker’s strong earnings report.  The stock saw trading volume hit 48.90 million yesterday, nearly three times the 10-day average. BSX has so far reached a 52-week high of $7.96, its 52-week low being $5.04.  It is currently trading above its 50-day moving average of $6.98 and above its 200-day moving average of $7.13.

    BSX s net income came to $146 million, or $0.10  per share, for the second quarter ended June 30, 2011. That compares to a net income of $98 million, or $0.06 per share, a year ago.  Adjusting to exclude net charges totaling $92 million, earnings were $0.12 per share, beating the $0.09 per share expected by analysts polled by FactSet Research.

    Sales for the quarter were $1.98 billion, which is at the higher end of the Company’s previous guidance range and representing an increase of 2.6% from $1.93 billion in the prior-year quarter. Analysts were looking for sales of $1.9 billion.

    Investors also welcomed the news that the Natick, Mass.-based company would buy back up to $1 billion of its stock, after reducing  its gross debt to $4.2 billion which is consistent with its targeted capital structure.  BSX president and CEO Ray Elliot said this repurchase program reflects BSX’s confidence in the strength of its long-term business prospects, earnings growth potential and its ability to generate strong cash flow.

    Following the upbeat earnings, the Company boosted its earnings guidance for the full year to a range of $0.64 to $0.70 per share, up from its prior view of $0.58 to $0.68.

    Financial Strength (28-July-2011)




    S&P 500

    Quick Ratio (MRQ) 1.31 1.40 2.10 0.64
    Current Ratio (MRQ) 1.75 1.70 2.67 1.01
    LT Debt to Equity (MRQ) 41.08 183.87 21.49 120.34
    Total Debt to Equity (MRQ) 43.31 228.49 26.19 158.43
    Interest Coverage (TTM) -6.13 2.99 1.76 19.9

    Source:, SEC Filings.

    Analyst Consensus

    This is the consensus forecast among 31 polled investment analysts. Against the Boston Scientific Corp company.

    Analyst Detail






    No Opinion

    Latest 5 3 20 2 1 0
    4 weeks ago 5 3 21 1 1 0
    2 months ago 4 3 20 1 1 0
    3 months ago 4 3 19 2 1 0
    Last year 4 3 16 1 1 0

    The 22 analysts offering 12-month price targets for BSX have a median target of 7.58, with a high estimate of 11.00 and a low estimate of 6.00. The median estimate represents a 12.89% increase from the last price of 6.71.


    Consensus Estimates Analysis

    # of Estimates




    1 Year Ago

    SALES (in millions)
    Quarter Ending Sep-11 22 1,902.19 1,952.00 1,866.00 2,016.82
    Quarter Ending Dec-11 22 1,975.86 2,027.44 1,913.00 2,087.47
    Year Ending Dec-11 25 7,767.31 8,330.00 7,615.33 8,058.46
    Year Ending Dec-12 25 7,918.18 8,216.00 7,722.00 8,340.86
    EARNINGS (per share)
    Quarter Ending Sep-11 22 0.08 0.13 0.06 0.09
    Quarter Ending Dec-11 22 0.10 0.13 0.08 0.11
    Year Ending Dec-11 26 0.40 0.46 0.35 0.41
    Year Ending Dec-12 26 0.49 0.59 0.39 0.55
    LT Growth Rate (%) 13 10.32 24.00 2.00 10.35

    Technical Analysis



    BSX is within its Bollinger Bands. This is a normal condition suggesting that it is neither overbought nor oversold relative to the recent levels.

    BSX’s MACD is indicating a weak bearish signal. Although the indicator is above the critical level of 0, which implies that the underlying moving averages are bullish, the MACD has crossed below its 9-day moving average or signal line. This suggests that positive momentum has begun to slow.

    Comparative Analysis

    Company Name Ticker Price per Mrkt. Cap. P/E P/S
    July28-2011 symbol Share, $ $ Mn 2011 2012 2011 2012
    St. Jude Medical Inc. STJ 47.08 15.48B 14.35 12.90 2.72 2.54
    Johnson & Johnson JNJ 65.50 179.54B 13.18 12.38 2.74 2.60
    Abbott Laboratories ABT 52.02 80.85B 11.23 10.45 2.08 1.99
    Medtronic Inc. MDT 36.36 6.05M 10.51 9.62 0.36 0.35
    Medical Instruments & Supplies Median       17.43 n/a 2.56 n/a
    Boston Scientific Corp. BSX 7.37 11.26B 18.43 15.04 1.45 1.42

    Source: Thomson Financial

    DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

    The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

    Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

    Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

    Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

    We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

    To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

    We encourage you to invest carefully and read investment information available at the websites of the SEC at and FINRA at

    Leave a Reply

    Your email address will not be published. Required fields are marked *